Last Updated: September 25, 2026

Claims for Patent: 10,435,666

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,435,666

Title:	Method for generating primate trophoblasts
Abstract:	The first method to cause a culture of human and other primate stem cells to directly and uniformly differentiate into a committed cell lineage is disclosed. Treatment of primate stem cells with a single protein trophoblast induction factor causes the cells to transform into human trophoblast cells, the precursor cells of the placenta. Several protein factors including bone morphogenic protein 4 (BMP4), BMP2, BMP7, and growth and differentiation factor 5 can serve as trophoblast-inducting factors.
Inventor(s):	Xu; Ren-He (Madison, WI), Thomson; James A. (Madison, WI)
Assignee:	WiCell Research Institute, Inc. (Madison, WI)
Application Number:	12/131,610
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,435,666
Patent Claims:	1. An in vitro culture comprising a substantially pure, replenishable population of synchronous primate trophoblast cells, wherein the synchronous primate trophoblast cells express chorionic gonadotropin, are predominantly chorionic gonadotropin-beta (CG-.beta.) positive, and are derived directly in vitro from undifferentiated primate embryonic stem cells exposed to a trophoblast inducing factor selected from the group consisting of bone morphogenetic protein 4 (BMP4), bone morphogenetic protein 2 (BMP2), bone morphogenetic protein 7 (BMP7), and growth and differentiation factor 5 (GDF5) without passing through an embryoid body stage. 2. An in vitro culture comprising a substantially pure, replenishable population of synchronous, mononuclear primate trophoblast cells, wherein the synchronous, mononuclear primate trophoblast cells express chorionic gonadotropin, are predominantly chorionic gonadotropin-beta (CG-.beta.) positive, and are derived directly in vitro from undifferentiated primate embryonic stem cells exposed to a trophoblast inducing factor selected from the group consisting of bone morphogenetic protein 4 (BMP4), bone morphogenetic protein 2 (BMP2), bone morphogenetic protein 7 (BMP7), and growth and differentiation factor 5 (GDF5) without passing through an embryoid body stage.

Details for Patent 10,435,666

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	15-Jan-74	⤷ Start Trial	2028-06-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	27-Dec-84	⤷ Start Trial	2028-06-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	15-Feb-85	⤷ Start Trial	2028-06-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	16-Feb-90	⤷ Start Trial	2028-06-02
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	26-Mar-74	⤷ Start Trial	2028-06-02
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	5-Mar-73	⤷ Start Trial	2028-06-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.